COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:

Chlorpheniramine maleate (113-92-8)


Study Results


Chronic Bioassay Level of Evidence

An overview of chronic evidence from Rats studies.
Rats
View
  • No Evidence, Male, Rats
View
  • No Evidence, Female, Rats
An overview of chronic evidence from Mice studies.
Mice
View
  • No Evidence, Male, Mice
View
  • No Evidence, Female, Mice

Genetic Toxicology

An overview of Genetic Toxicology Micronucleus Mice study conclusions related to Chlorpheniramine maleate (113-92-8).
Micronucleus - Mice
View
  • Male: Negative
An overview of Genetic Toxicology Micronucleus Rats study conclusions related to Chlorpheniramine maleate (113-92-8).
Micronucleus - Rats
View
  • Male: Negative
An overview of Genetic Toxicology Mammalian Cell Mutagenicity study conclusions related to Chlorpheniramine maleate (113-92-8).
Mammalian Cell Mutagenicity
View
  • Negative
An overview of Genetic Toxicology Mammalian Cell Cytogenetics study conclusions related to Chlorpheniramine maleate (113-92-8).
Mammalian Cell Cytogenetics
CA SCE
An overview of Genetic Toxicology Bacterial Mutagenicity study conclusions related to Chlorpheniramine maleate (113-92-8).
Bacterial Mutagenicity
View
  • Negative

Citation Information


NTP. Chlorpheniramine maleate (113-92-8). Chemical Effects in Biological Systems (CEBS). Research Triangle Park, NC (USA): National Toxicology Program (NTP).

Publications


TR-317 Toxicology and Carcinogenesis Studies of Chlorpheniramine Maleate (CASRN 113-92-8) in F344/N Rats and B6C3F1 Mice (Gavage Studies)
Mortelmans, K., Haworth, S., Lawlor, T., Speck, W., Tainer, B., and Zeiger, E. Salmonella mutagenicity tests. II. Results from the testing of 270 chemicals Environ. Mutagen. Vol. 8 (Suppl 7) (1986) 1-119
McGregor, D., Brown, A., Howgate, S., McBride, D., Riach, C., and Caspary, W. Responses of the L5178Y tk+/tk- mouse lymphoma cell forward mutation assay. IV: 27 coded chemicals. Environ. Molec. Mutagen. Vol. 17 (1991) 196-219
Myhr B.C., McGregor, D., Bowers, L., Riach, C., Brown, A., Edwards, I., McBride, D., Martin, R., and Caspary, W.J. L5178Y mouse lymphoma cell mutation assay results with 41 compounds. Environ. Molec. Mutagen. Vol. 16 (Suppl 18) (1990) 138-167
Anderson, B.E., Zeiger, E., Shelby, M.D., Resnick, M.A., Gulati, D.K., Ivett, J.L., and Loveday, K.S. Chromosome aberration and sister chromatid exchange test results with 42 chemicals. Environ. Molec. Mutagen. Vol. 16 (Suppl 18) (1990) 55-137

Study Data


Toxicity and Carcinogenicity Studies


Evaluation of the Chronic Toxicity and Carcinogenicity of Chlorpheniramine Maleate (113-92-8) in Male F344 Rats Exposed via Gavage
Evaluation of the Chronic Toxicity and Carcinogenicity of Chlorpheniramine Maleate (113-92-8) in Female F344 Rats Exposed via Gavage
Evaluation of the Chronic Toxicity and Carcinogenicity of Chlorpheniramine Maleate (113-92-8) in Male B6C3F1 Mice Exposed via Gavage
Evaluation of the Chronic Toxicity and Carcinogenicity of Chlorpheniramine Maleate (113-92-8) in Female B6C3F1 Mice Exposed via Gavage

Genetic Toxicology Studies


Genetic Toxicity Evaluation of Chlorpheniramine Maleate (113-92-8) in Micronucleus Study A45472 in B6C3F1 Mice
Genetic Toxicity Evaluation of Chlorpheniramine Maleate (113-92-8) in Micronucleus Study A98719 in F344 Rats
Genetic Toxicity Evaluation of Chlorpheniramine Maleate in Salmonella/E.coli Mutagenicity Test or Ames Test. Study 543950
Summary Data

Other NTP Studies


ADME/TK Evaluation (S0129) of Chlorpheniramine maleate (113-92-8) in F344 Rats Exposed via Gavage Administration and Intravenous Injection